Co-Authors
This is a "connection" page, showing publications co-authored by MURALI CHINTAGUMPALA and JACK SU.
Connection Strength
2.013
-
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma. Cancer. 2021 Oct 15; 127(20):3865-3871.
Score: 0.200
-
Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer. 2021 07 01; 127(13):2358-2367.
Score: 0.196
-
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
Score: 0.172
-
Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
Score: 0.157
-
Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer. 2013 Jul 15; 119(14):2654-9.
Score: 0.113
-
Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
Score: 0.113
-
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
Score: 0.094
-
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
Score: 0.091
-
Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):214-21.
Score: 0.080
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Jun 25.
Score: 0.061
-
Fractionated radiation therapy alters energy metabolism and induces cellular quiescence exit in patient-derived orthotopic xenograft models of high-grade glioma. Transl Oncol. 2024 Jul; 45:101988.
Score: 0.061
-
Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. Nat Commun. 2022 11 05; 13(1):6689.
Score: 0.055
-
Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. Transl Oncol. 2022 Apr; 18:101368.
Score: 0.052
-
Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. Adv Sci (Weinh). 2021 12; 8(23):e2101923.
Score: 0.051
-
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021 11 08; 39(11):1519-1530.e4.
Score: 0.051
-
Gadolinium is not necessary for surveillance MR imaging in children with chiasmatic-hypothalamic low-grade glioma. Pediatr Blood Cancer. 2021 10; 68(10):e29178.
Score: 0.050
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
Score: 0.048
-
Corrigendum to "Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors" [Cancer Lett. 493 (2020) 197-206]. Cancer Lett. 2021 Mar 01; 500:294.
Score: 0.048
-
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.039
-
Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy. Clin Transl Radiat Oncol. 2016 Dec; 1:9-14.
Score: 0.036
-
Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
Score: 0.035
-
Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol. 2015 Feb; 114(2):224-9.
Score: 0.032
-
Silencing BMI1 eliminates tumor formation of pediatric glioma CD133+ cells not by affecting known targets but by down-regulating a novel set of core genes. Acta Neuropathol Commun. 2014 Dec 20; 2:160.
Score: 0.032
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
Score: 0.032
-
Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas. J Neurooncol. 2014 Nov; 120(2):293-301.
Score: 0.031
-
A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro Oncol. 2014 Jun; 16(6):787-99.
Score: 0.030
-
Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report. J Neurosurg. 2007 Aug; 107(2 Suppl):137-42.
Score: 0.019
-
Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 2006 Dec 01; 66(23):11172-8.
Score: 0.018
-
Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84.
Score: 0.016